Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors), By Region, And Segment Forecasts, 2019 - 2025

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Breast cancer drug Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increased incidence and prevalence rate of cancer worldwide
3.1.1.2 High investments in R & D
3.1.1.3 Increasing preference for targeted therapy approach in breast cancer treatment
3.1.1.4 Rise in the number of pipeline drugs.
3.1.1.5进步通过r biology & pharmacology
3.1.2 Market Restrain Analysis
3.1.2.1 Stringent regulatory guidelines
3.1.2.2 Expiry of patented drugs
3.1.2.3 Complications associated with chemotherapy
3.2 Penetration & growth prospect mapping
3.3 Breast cancer drug - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Breast cancer drug: Type Scope Estimates & Trend Analysis
4.1 Breast cancer drug market: application scope movement analysis
4.2 HER2 inhibitor
4.2.1 HER2 inhibitor market, 2014 - 2025 (USD Million)
4.3 Mitotic inhibitor
4.3.1 Mitotic inhibitor market, 2014 - 2025 (USD Million)
4.4 Anti-metabolites
4.4.1 Anti- metabolites market, 2014 - 2025 (USD Million)
4.5 Aromatase inhibitor
4.5.1 Aromatase inhibitor market, 2014 - 2025 (USD Million)
4.6 CDK 4/6 inhibitor
4.6.1 CDK 4/6 inhibitor market, 2014 - 2025 (USD Million)
4.7 Hormonal receptor
4.7.1 Hormonal receptor market, 2014 - 2025 (USD Million)
Chapter 5 Breast cancer drug: Regional Estimates & Trend Analysis,
5.1 Breast cancer drug market share by region, 2016 & 2025
5.2 North America
5.2.1北美Breast cancer drug market, 2014 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. Breast cancer drug market, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada Breast cancer drug market, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe Breast cancer drug market, 2014 - 2025 (USD Million)
5.3.2 Germany
5.3.2.1 Germany Breast cancer drug market, 2014 - 2025 (USD Million)
5.3.3 U.K.
5.3.3.1 U.K. Breast cancer drug market, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Breast cancer drug market, 2014 - 2025 (USD Million)
5.4.2 China
5.4.2.1 China Breast cancer drug market, 2014 - 2025 (USD Million)
5.4.3 Japan
5.4.3.1 Japan Breast cancer drug market, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America Breast cancer drug market, 2014 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil Breast cancer drug market, 2014 - 2025 (USD Million)
5.6 Middle East and Africa
5.6.1 Middle East and Africa Breast cancer drug market, 2014 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa Breast cancer drug market, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy framework
6.2 Market participation categorization
6.2.1 Novartis AG
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Technique benchmarking
6.2.1.4 Strategic initiatives
6.2.2 Pfizer Inc.
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Technique benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Merck & Co Inc.
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Technique benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Janssen Global Services LLC
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Technique benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Celgene Corporation
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Technique benchmarking
6.2.5.4 Strategic initiatives
6.2.6 Astellas Pharma Inc.
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Technique benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Genzyme Corporation
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Technique benchmarking
6.2.7.4 Strategic initiatives
6.2.8 F. Hoffman-La Roche Pvt. Ltd
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Technique benchmarking
6.2.8.4 Strategic initiatives
6.2.9 AstraZeneca
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Technique benchmarking
6.2.9.4 Strategic initiatives
6.2.10 AbbVie, Inc.
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Technique benchmarking
6.2.10.4 Strategic initiatives
6.2.11 Genentech, Inc.
6.2.11.1 Company overview
6.2.11.2 Financial performance
6.2.11.3 Technique benchmarking
6.2.11.4 Strategic initiatives
6.2.12 MacroGenics Inc.
6.2.12.1 Company overview
6.2.12.2 Financial performance
6.2.12.3 Technique benchmarking
6.2.12.4 Strategic initiatives
6.2.13 Celldex Therapeutics.
6.2.13.1 Company overview
6.2.13.2 Financial performance
6.2.13.3 Technique benchmarking
6.2.13.4 Strategic initiatives
6.2.14 Onyx Pharmaceuticals, Inc.
6.2.14.1 Company overview
6.2.14.2 Financial performance
6.2.14.3 Technique benchmarking
6.2.14.4 Strategic initiatives
6.2.15 BioNumerik Pharmaceuticals Inc.
6.2.15.1 Company overview
6.2.15.2 Financial performance
6.2.15.3 Technique benchmarking
6.2.15.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 HER2 inhibitor drugs
TABLE 3 Herceptin drugs
TABLE 4 Herceptin drugs
TABLE 5 Hormone Receptor drugs
TABLE 6 Perjeta drugs
TABLE 7 Kadcyla drugs
TABLE 8 Mitotic inhibitor drugs
TABLE 9 Halaven drug
TABLE 10 Taxotere drug
TABLE 11 Ixempra drugs
TABLE 12 Anti-metabolites drugs
TABLE 13 Aromatase inhibitors drugs
TABLE 14 Hormone Receptor drugs
TABLE 15 Aromasin drugs
TABLE 16 Arimidex drug
TABLE 17 Ibrance drug
TABLE 18 Afinitor drug
TABLE 19 Hormone Receptor drugs
TABLE 20 Zoladex drug
TABLE 21 Faslodex drug
TABLE 22 Fareston drugs
TABLE 23 North America breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 24 U.S. breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 25 Canada breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 26 Europe breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 27 U.K. breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 28 Germany breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 29 Asia Pacific breast cancer drug market estimates and forecasts, by type, 2014 - 2025(USD Million)
TABLE 30 Japan breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 31 China breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 32 India breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 33 Latin America breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 34 Brazil breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 35 Mexico breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 36 MEA breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 37 South Africa breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market Summary
图6市场趋势&look
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 R & D Spending’s (2015 - 16)
FIG. 10 Breast Cancer pipeline drugs
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Breast Cancer Drug market type of synthesis outlook key takeaways
FIG. 16 Breast Cancer Drug market: Type movement analysis
FIG. 17 Global HER2 inhibitorsmarket, 2014 - 2025 (USD Million)
FIG. 18 Global antimetabolites market, 2014 - 2025 (USD Million)
FIG. 19 Global mitotic inhibitors market, 2014 - 2025 (USD Million)
FIG. 20 Global CDK 4/6 inhibitors market, 2014 - 2025 (USD Million)
FIG. 21 Global hormone receptor market, 2014 - 2025 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Regional outlook, 2015 & 2024 5
FIG. 24 North America Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 25 U.S. Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 26 Canada Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 27 Europe Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 28 U.K. Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 29 Germany Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 30 Asia-Pacific Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 31 Japan Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 32 China Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 33 India Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 34 Latin America Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 35 Brazil Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 36 Mexico Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 37 MEA Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 38 South Africa Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 39 Strategy framework
FIG. 40 Participant categorization